Management of hepatitis C in HIV- infected patients

Current Infectious Disease Reports

Volumn 7, Issue 2, 2005, Pages 91-102

  Rodriguez, Benigno ^a   Bobak, David A ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANALGESIC AGENT; ANTIPYRETIC AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CILUPREVIR; CITALOPRAM; DIDANOSINE; DNA POLYMERASE; FLUOXETINE; HELICASE; INOSINATE DEHYDROGENASE; MITOCHONDRIAL DNA; OXIDOREDUCTASE; PAROXETINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RIBAMIDINE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; STAVUDINE; UNINDEXED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACUTE PANCREATITIS; ALOPECIA; ANEMIA; ANTIBODY DETECTION; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLINICAL TRIAL; CYTOPENIA; DEPRESSION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME IMMUNOASSAY; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDRATION; HYPERLACTATEMIA; IMMUNE RESPONSE; IMMUNOBLOTTING; LABORATORY TEST; LACTIC ACIDOSIS; LEUKOPENIA; LIVER BIOPSY; LIVER TOXICITY; MEDICAL DECISION MAKING; MOOD DISORDER; MORBIDITY; MORTALITY; NEUTROPENIA; NONHUMAN; PATIENT CARE; PRACTICE GUIDELINE; REVIEW; SLEEP DISORDER; SURVIVAL RATE; THYROID DISEASE; VIROLOGY;

EID: 17044412641     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0067-0     Document Type: Review

References (129)

1. World Health Organization: Hepatitis C - global prevalence (update). Wkly Epidemiol Rec 1999, 74:425-427.
2. Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of the hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999, 341:556-562.
3. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998, 47: -39.
4. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
5. Murphy EL, Collier AC, Kalish LA, et al.: Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001, 135: 7-26.
6. Soriano V, Garcia-Samaniego J, Valencia E, et al.: Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999, 15:1-4.
7. Macias J, Pineda JA, Leal M, et al.: Influence of hepatitis C virus infection on the mortality of antiretroviral-treated patients with HIV disease. Eur J Clin Microbiol Infect Dis 1998, 17:167-170.
8. Bica I, McGovern B, Dhar R, et al.: Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001, 32: 92-497.
9. Martin-Carbonero L, Soriano V, Valencia E, et al.: Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001, 17:1467-1471.
10. Selik RM, Byers RH Jr, Dworkin MS: Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002, 29:378-387.
11. Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ: Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994, 84:1020-1023.
12. Benhamou Y, Bochet M, Martino V, et al.: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999, 30:1054-1058.
13. Rockstroh JK, Spengler U, Sudhop T, et al.: Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996, 91:2563-2568.
14. Puoti M, Bonacini M, Spinetti A, et al.: Liver fibrosis progression is related to CD4 cell depletion in patients coinfected wit hepatitis C virus and human immunodeficiency virus. J Infect Dis 2001, 183:134-137.
15. Greub G, Ledergerber B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805.
16. Bruno R, Sacchi P, Filice C, et al.: Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. J Acquir Immune Defic Syndr 2002, 30:535-536.
17. Di Martino V, Rufat P, Boyer N, et al.: The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001, 34::1193-1199.
18. Monforte Ade A, Bugarini R, Pezzotti P, et al.: Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001, 28:114-123.
19. Ammassari A, Trotta MP, Cozzi-Lepri A, et al.: Hepatitis C virus co-infection increases risk of non-adherence to highly active antiretroviral therapy (HAART) in HIV-infected persons [abstract 793]. Paper presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, October 29-November 2, 2004.
20. Melvin DC, Lee JK, Belsey E, et al.: The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 2000, 14:463-465.
21. Fleming CA, Craven DE, Thornton D, et al.: Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003, 36:97-100.
22. Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34:831-837.
23. Bove JR: Transfusion-associated hepatitis and AIDS. What is the risk? N Engl J Med 1987, 317:242-245.
24. Darby SC, Ewart DW, Giangrande PL, et al.: Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organization. Lancet 1997, 350:1425-1431.
25. Rauch A, Rickenbach M, Weber R, et al.: Incidence of hepatitis C virus infection in the Swiss HIV Cohort Study [abstract MoPeb3335]. Paper presented at the XV International AIDS Conference. Bangkok, Thailand, July 11-16, 2004.
26. Staples CT Jr, Rimland D, Dudas D: Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999, 29:150-154.
27. Mathei C, Buntinx F, van Damme P. Seroprevalence of hepatitis C markers among intravenous drug users in western European countries: a systematic review. J Viral Hepat 2002, 9: 57-173.
28. Roy K, Hay G, Andragetti R, Taylor A, et al.: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 2002, 129:577-585.
29. Yee TT, Griffioen A, Sabin CA, et al.: The natural history of HCV in a cohort of haemophilic patients infected between 1961 and 1985. Gut 2000, 47:845-851.
30. Thomas DL, Astemborski J, Rai RM, et al.: The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
31. Bonacini M, Lin HJ, Hollinger FB: Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001, 26:340-344.
32. Daar ES, Lynn H, Donfield S, et al.: Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr 2001, 26:466-472.
33. Gibb DM, Goodall RL, Dunn DT, et al.: Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000, 356: 04-907.
34. Zanetti AR, Tanzi E, Romano L, et al.: Multicenter trial on mother-to-infant transmission of GBV-C virus. The Lombardy Study Group on Vertical/Perinatal Hepatitis Viruses Transmission. J Med Virol 1998, 54:107-112.
35. Thomas DL, Villano SA, Riester KA, et al.: Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 1998, 177:1480-1488.
36. Eyster ME, Alter HJ, Aledort LM, et al.: Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991, 115: 64-768.
37. Thomas DL, Shih JW, Alter HJ, et al.: Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 1996, 174:690-695.
38. Serfaty L, Costagliola D, Wendum D, et al.: Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study. AIDS 2001, 15:2011-2016.
39. Giordano TP, Kramer JR, Souchek J, et al.: Does HCV co-infection increase the incidence of non-alcoholic cirrhosis and hepatocellular carcinoma? A cohort study of HIV-infected US Veterans, 1992-2001 [abstract 213]. Paper presented at the 2nd IAS Conference on HIV Pathogenesis and Treatment. Paris, July 2003. Antivir Ther 2003, 8(suppl 1):S235.
40. Eyster ME, Diamondstone LS, Lien JM, et al.: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1993, 6: 02-610.
41. Ragni MV, Belle SH: Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 2001, 183:1112-1115.
42. Soto B, Sanchez-Quijano A, Rodrigo L, et al.: Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997, 26:1-5.
43. Cacoub P, Geffray L, Rosenthal E, et al.: Mortality among human immunodeficiency virus-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001, 32:1207-1214.
44. Macias J, Melguizo I, Fernandez-Rivera FJ, et al.: Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002, 21:775-781.
45. Graham CS, Baden LR, Yu E, et al.: Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001, 33: 62-569.
46. Fultz SL, Chang CC, Skanderson M, et al.: Survival in patients coinfected with HIV and hepatitis C in the HAART era [abstract MoPeB3318]. Paper presented at the XV International AIDS Conference. Bangkok, Thailand, July 11-16, 2004.
47. Sabin CA, Telfer P, Phillips AN, et al.: The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men. J Infect Dis 1997, 175:164-168.
48. Piroth L, Duong M, Quantin C, et al.: Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients? AIDS 1998, 12:381-388.
49. Dorrucci M, Pezzotti P, Phillips AN, et al.: Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. J Infect Dis 1995, 172:1503-1508.
50. Quan CM, Krajden M, Grigoriew GA, Salit IE: Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 1993, 17:117-119.
51. Wright TL, Hollander H, Pu X, et al.: Hepatitis C in HIV-infected patients with and without AIDS: prevalence and relationship to patient survival. Hepatology 1994, 20:1152-1155.
52. Sulkowski MS, Moore RD, Mehta SH, et al.: Hepatitis C and progression of HIV disease. JAMA 2002, 288:199-206.
53. Rancinan C, Neau D, Saves M, et al.: Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy? AIDS 2002, 16: 357-1362.
54. Tedaldi EM, Baker RK, Moorman AC, et al.: Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2003, 36:363-367.
55. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74-80.
56. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al.: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895-2902.
57. Quirishi N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362: 708-1713.
58. Sabin CA, Walker AS, Dunn D: HIV/HCV coinfection, HAART, and liver-related mortality. Lancet 2004, 362:757-758; author reply 758.
59. John M, Flexman J, French MA: Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998, 12: 289-2293.
60. Martin-Carbonero L, Nunez M, Rios P, et al.: Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. AIDS 2002, 16:1423-1425.
61. Kottilil S, Polis MA, Kovacs JA: HIV Infection, hepatitis C infection, and HAART: hard clinical choices. JAMA 2004, 292:243-250.
62. Sulkowski MS, Thomas DL: Hepatitis C in the HIV-infected person. Ann Intern Med 2003, 138:197-207.
63. Sulkowski MS, Thomas DL, Mehta SH, et al.: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002, 35:182-189.
64. Thomas DL: Hepatitis C and human immunodeficiency virus infection. Hepatology 2002, 36(Suppl 1):S201-S209.
65. Aceti A, Pasquazzi C, Zechini B, De Bac C: Hepatotoxicity development during antiretroviral therapy cantaining protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002, 29:41-48.
66. Rimland d, Guest JL, Anderson KB: The effect of hepatitis C co-infection on survival in the Atlanta VA Cohort Study (HAVACS) in the post-HAART era. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 24-28, 2002.
67. Braitstein P, Asselin JJ, Montessori V, et al.: The impact of the hepatitis C virus (HCV) on CD4 response post initiation of HAART among a population-based HIV treatment cohort. Presented at the 2nd International AIDS Society Conference on HIV Disease and Pathogenesis, abstract 214. Antivir Ther 2003, 8(Suppl 1):S235-S236.
68. Cowling BJ, Donnelly CA, Ghani AC, et al.: Virologic and immunologic response to antiretroviral therapy among HIV patients co-infected with hepatitis C virus (HCV) - analysis of a 6,401 HIV patient cohort [abstract B3300]. Paper presented at the XV International AIDS Conference. Bangkok, Thailand, July 11-16, 2004.
69. Dronda F, Zamora J, Moreno S, et al.: CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS 2004, 18: 210-2212.
70. Adinolfi LE, Andreana A, Utili R, et al.: HCV RNA levels in serum, liver, and peripheral blood mononuclear cells of chronic hepatitis C patients and their relationship to liver injury. Am J Gastroenterol 1998, 93:2162-2166.
71. Penning M, Beld M, Goudsmit J: Peripheral blood mononuclear cells of HIV- and HCV-antibody-positive individuals contain HCV RNA but no HCV DNA despite evidence for reverse transcription of HIV RNA into DNA. Virology 2000, 268:12-16.
72. Meier V, Mihm S, Braun Weitzke P, Ramadori G: HCV-RNA positivity in peripheral blood mononuclear cells of patients with chronic HCV infection: does it really mean viral replication? World J Gastroenterol 2001, 7:228-234.
73. Gong GZ, Lai LY, Jiang YF, et al.: HCV replication in PBMC and its influence on interferon therapy. World J Gastroenterol 2003, 9:291-294.
74. Valdez H, Anthony D, Farukhi F, et al.: Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 2000, 14: 239-2246.
75. De Luca A, Bugarini R, Lepri AC, et al.: Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects. Arch Intern Med 2002, 162:2125-2132.
76. Vigano A, Saresella M, Villa ML, et al.: CD38+CD8+ T cells as a maker of poor response to therapy in HIV-infected individuals. Chem Immunol 2000, 75:207-217.
77. Taya N, Torimoto Y, Shindo M, et al.: Fas-mediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C. Br J Haematol 2000, 110:89-97.
78. Treating opportunistic infections among HIV-infected adults and adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2004, 53:50-53.
79. Thio CL, Nolt KR, Astemborski J, et al.: Screening for hepatitis C virus in human immunodeficiency virus-infected individuals. J Clin Microbiol 2000, 38:575-577.
80. Berggren RA, Jain R, Hester J, et al.; False-negative hepatitis C antibody is associated with low CD4 cell counts in HIV/HCV coinfected patients [abstract 562]. Paper presented at the 8th Conference on Retroviruses and Oppurtunistic Infections. Chicago, IL, February 4-8, 2001.
81. George SL, Gebhardt J, Klinzman D, et al.: Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 2002, 31:154-162.
82. Dieterich DT: Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection. Am J Med 1999, 107: 9S-84S.
83. Villano SA, Vlahov D, Nelson KE, et al.: Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999, 29:908-914.
84. Child CG, Turcotte JG: Surgery and portal hypertension. In The Liver and Portal Hypertension. Edited by Child CG. Philadelphia: WB Saunders; 1964:50-64.
85. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997, 349: 25-832.
86. Pessione F, Degos F, Marcellin P, et al.: Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998, 27: 717-1722.
87. Kouvatsos P, Doerfler RE, Woodward WC: ALT does not predict hepatic fibrosis in HIV/HCV co-infected patients on antiretroviral therapy [abstract WePeB6040]. Paper presented at the XIV International AIDS Conference. Barcelona, Spain, July 7-12, 2002.
88. Benhamou Y, Di Martino V, Bochet M, et al.: Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001, 34:283-287.
89. Poynard T, Ratziu V, Charlotte F, et al.: Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34:730-739.
90. Poles MA, Dieterich DT, Schwartz ED, et al.: Liver biopsy findings in 501 patients infected with human immunodeficiency virus (HIV). J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:170-177.
91. Quereda C, Moreno S, Moreno L, et al.: The role of liver biopsy in the management of chronic hepatitis C in patients infected with the human immunodeficiency virus. Hum Pathol 2004, 35:1083-1087.
92. Soriano V, Puoti M, Sulkowski M, et al.: Care of patients with hepatitis C and HIV co-infection. AIDS 2004, 18:1-12.
93. Fonquernie L, Serfaty L, Charrois A, et a;.: Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients. HIV Med 2004, 5:385-390.
94. Marcellin P, Boyer N, Gervais A, et al.: Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997, 127: 75-881.
95. Soriano V, Garcia-Samaniego J, Bravo R, et al.: Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996, 23:585-591.
96. Kostman JR, Smith J, Giffen CA, Frost KR: Interferon alfa-2b/ribavirin combination therapy in HCV/HIV co-infected persons: results of a multi-center, randomized, double-blind, placebo-controlled trial [abstract 634]. Hepatology 2001, 34:330A.
97. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351: 38-450.
98. Taylor LE, Rich JD, Tashima KT, et al.: Peginterferon plus ribavirin for hepatitis C in HIV-infected patients. N Engl J Med 2004, 351:2340-2342.
99. Chung RT, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004, 351:451-459.
100. Carrat F, Bani-Sadr F, Pol S, et al.: Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004, 292:2839-2848.
101. McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
102. Bressler BL, Guindi M, Tomlinson G, Heathcote J: High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003, 38: 39-644.
103. Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004, 350:2265-2271.
104. Hadziyannis SJ, Sette H Jr, Morgan TR, et al.: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004, 140:346-355.
105. Shiffman ML, Di Biscegli AM, Lindsay KL, et al.: Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004, 126: 015-1023; discussion 947.
106. Ishii K, Matsamaru K, Wakui N, et al.: Early immune-mediated response to ribavirin combined with IFN in patients with chronic hepatitis C [abstract 399]. Paper presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, October 29-November 2, 2004.
107. Crespo M, Esteban JI, Sauleda S, et al.: Early prediction of sustained virologic response (SVR) in patients with chronic hepatitis C (CHC) and HIV infection treated with IFN + RBV [abstract 428]. Paper presented at the 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, October 29-November 2, 2004.
108. Moreno A, Garcia S, Moreno L: Negative prognostic value of HCV RNA decline at 4 weeks of treatment in both HCV-monoinfected and HCV/HIV-coinfected patients [abstract V-777]. Paper presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotheraphy. Chicago, IL, September 14-17, 2003.
109. Fattovich G, Giustina G, Favarato S, Ruol A: A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996, 24:38-47.
110. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000, 157:867-876.
111. Dieperink E, Ho SB, Tetrick L, et al.: Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C. Gen Hosp Psychiatry 2004, 26: 37-240.
112. Dieperink E, Ho SB, Thuras P, Willenbring ML: A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003, 44:104-112.
113. Levenson JL, Fallon HJ: Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol 1993, 88: 60-761.
114. Schramm TM, Lawford BR, Macdonald GA, Cooksley WG: Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust 2000, 173:359-361.
115. Gleason OC, Yates WR: Five cases of interferon-alpha-induced depression treated with antidepressant therapy. Psychosomatics 1999, 40:510-512.
116. Landau A, Batisse D, Piketty C, et al.: Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients. AIDS 2001, 15:2149-2155.
117. Dieterich DT: Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002, 185(Suppl 2):S128-S137.
118. Baba M, Pauwels R, Balzarini J, et al.: Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2-pm,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987, 31:1613-1617.
119. Hoggard PG, Kewn S, Barry MG, et al.: Effects of drugs on 2-pm,3′-dideoxy-2′,3′-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother 1997, 41:1231-1236.
120. Vogt MW, Hartshorn KL, Furman PA, et al.: Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987, 235:1376-1379.
121. Blatt LM, Davis JM, Klein SB, Taylor MW: The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996, 16:489-499.
122. Tong MJ, Reddy KR, Lee WM, et al.: Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997, 26:747-754.
123. Osborn BL, Olsen HS, Nardelli B, et al.: Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002, 303:540-548.
124. Sung C, Nardelli B, LaFleur DW, et al.: An IFN-beta-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J Interferon Cytokine Res 2003, 23:25-36.
125. Pockros PJ, for the Pegasys/Levovirin Study Group: Combination of levovirin and peginterferon alfa-2a fails to generate virological response comparable to ribavirin-peginterferon alfa-2a combination therapy in patients with chronic HCV [abstract 525]. Paper presented at the 55th Annual Meeting of The American Association for the Study of Liver Disease. Boston, MA, October 29-November 2, 2004.
126. Gish RG, Arora S, Nelson D: Safety and efficacy of viramidine in combination with pegylated interferon alfa-2a for treatment of hepatitis C in therapy-naive patients [abstract 479/762]. Paper presented at the 39th Annual Meeting of The European Association for the Study of the Liver. Berlin, Germany, April 14-18, 2004.
127. Hinrichsen H, Benhamou Y, Wedemeyer H, et al.: Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004, 127:1347-1355.
128. Duclow-Vallee JD, Vittecoq D, Teicher E: Experience of liver transplantation (LT) in 20 HIV-HCV co-infected patients in the highly active antiretroviral (HAART) era 2000-2004 [abstract 69]. Paper presented at the 55th Annual Meeting of The American Association for the Study of Liver Diseases. Boston, MA, October 29-November 2, 2004.
129. Fung J, Eghtesad B, Patel-Tom K, et al.: Liver transplantation in patients with HIV infection. Liver Transpl 2004, 10(Suppl 2):S39-S53.